Dass joins Masood Khan, senior director of immunoanalytical science and technology at the Shawnee, Kansas-based firm. He will assist with the development of GLP-compliant and non-GLP assays for the conduct of large molecule bioanalytical studies, including PK/TK analysis, immunogenicity evaluation and biomarker quantification.
KCAS uses state-of-the-art immunoanalytical technologies to support large molecule bioanalysis for preclinical and clinical studies (Phase I - IV), as well as rapid bioanalysis for biomarker screening pilot projects.
‘We are very fortunate to have both Dr Khan and Dr Dass at KCAS,’ said president and scientific director Dari Dadgar.
‘Their combined knowledge and skill in working with large molecules, specifically LBA services, has positively impacted our capabilities and we look forward to propelled growth and expansion in the future.’
KCAS has recently purchased Meso Scale Discovery’s Sector Imager 6000, an electrochemiluminescence (ECL) detection technology, which will enable the company to offer immunogenicity assays with better drug tolerance and multi-plex panels for biomarker assays.
KCAS expands ligand binding assay team
Proveen Dass joins the company as associate director
You may also like
Manufacturing
The story of an East-West German company | 150 years of Romaco Kilian
Kilian’s story tells of the rise, fall and resurgence of a Berlin company steeped in tradition, which is now based in Cologne. It is the story of the entrepreneur Fritz Kilian, who turned a small locksmith’s workshop in Berlin into a successful company that is still a leading manufacturer of tablet presses today. It is the story of a visionary whose legacy has endured the test of time and continues to this day
Manufacturing
ystral expands India footprint with new Bangalore facility to support Asian markets
German mixing and process technology specialist ystral has opened a new facility in Bangalore, strengthening its Indian operations and laying the groundwork for a regional service hub supporting fast-growing Asian markets
Manufacturing
Why aseptic processing is critical for microsphere drug manufacturing
As microsphere-based drug delivery systems move from niche innovation to commercial reality, manufacturers face growing pressure to guarantee sterility without compromising product integrity. Aseptic processing has become essential to meeting both regulatory expectations and patient safety requirements